1. Home
  2. JVA vs HIND Comparison

JVA vs HIND Comparison

Compare JVA & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JVA

Coffee Holding Co. Inc.

HOLD

Current Price

$3.50

Market Cap

17.8M

ML Signal

HOLD

Logo Vyome Holdings Inc.

HIND

Vyome Holdings Inc.

HOLD

Current Price

$2.14

Market Cap

15.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
JVA
HIND
Founded
1971
2017
Country
United States
United States
Employees
N/A
18
Industry
Packaged Foods
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
17.8M
15.2M
IPO Year
1997
2016

Fundamental Metrics

Financial Performance
Metric
JVA
HIND
Price
$3.50
$2.14
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$15.00
AVG Volume (30 Days)
37.8K
11.9K
Earning Date
06-12-2026
05-20-2026
Dividend Yield
1.71%
N/A
EPS Growth
N/A
N/A
EPS
0.33
N/A
Revenue
$90,655,294.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.48
N/A
Revenue Growth
17.54
N/A
52 Week Low
$2.93
$1.75
52 Week High
$5.62
$12.87

Technical Indicators

Market Signals
Indicator
JVA
HIND
Relative Strength Index (RSI) 40.98 41.01
Support Level $3.28 $2.02
Resistance Level $3.72 $2.33
Average True Range (ATR) 0.10 0.08
MACD 0.03 -0.01
Stochastic Oscillator 29.42 4.17

Price Performance

Historical Comparison
JVA
HIND

About JVA Coffee Holding Co. Inc.

Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.

About HIND Vyome Holdings Inc.

Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Share on Social Networks: